Steven Cohen Janux Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 136,430 shares of JANX stock, worth $6.59 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
136,430
Previous 136,430
-0.0%
Holding current value
$6.59 Million
Previous $5.72 Million
-0.0%
% of portfolio
0.02%
Previous 0.02%
Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
161Shares Held
36.8MCall Options Held
72.2KPut Options Held
103K-
Ra Capital Management, L.P. Boston, MA9.17MShares$443 Million5.79% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.98MShares$144 Million3.01% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$113 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.33MShares$112 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X01.8MShares$87.1 Million0.04% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.01B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...